Expression of IL-12 receptor subunits on PBMCs
Lymphocyte subset . | Control PBMCs . | Patient PBMCs . | P . |
|---|---|---|---|
| % IL-12Rβ1+ T cells | 14 ± 4 | 85 ± 4 | ≤ .001 |
| % IL-12Rβ2+ T cells | 8 ± 2 | 14 ± 3 | > .1 |
| % IL-12Rβ1+ NK cells | 73 ± 7 | 88 ± 2 | ≤ .01 |
| % IL-12Rβ2+ NK cells | 1 ± 1 | 4 ± 1 | ≤ .025 |
Lymphocyte subset . | Control PBMCs . | Patient PBMCs . | P . |
|---|---|---|---|
| % IL-12Rβ1+ T cells | 14 ± 4 | 85 ± 4 | ≤ .001 |
| % IL-12Rβ2+ T cells | 8 ± 2 | 14 ± 3 | > .1 |
| % IL-12Rβ1+ NK cells | 73 ± 7 | 88 ± 2 | ≤ .01 |
| % IL-12Rβ2+ NK cells | 1 ± 1 | 4 ± 1 | ≤ .025 |
Values are mean ± SE of the percentage of T cells or NK cells that coexpress the indicated IL-12 receptor subunits, as determined by flow cytometry. PBMCs were obtained from 10 patients with lymphoma at a median of 3 months after transplantation.